1293915-42-0

Basic information

• Product Name: 5-HexynaMide, 6-[2-[[4-aMino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyriMidin-1-yl]Methyl]-3-[(2-chlorophenyl)Methyl]-3,4-dihydro-4-oxo-5-quinazolinyl]-N,N-bis(2-Methoxyethyl)-
• Synonyms: 5-HexynaMide, 6-[2-[[4-aMino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyriMidin-1-yl]Methyl]-3-[(2-chlorophenyl)Methyl]-3,4-dihydro-4-oxo-5-quinazolinyl]-N,N-bis(2-Methoxyethyl)-;6-(2-((4-Amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide;6-[2-[[4-Amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[(2-chlorophenyl)met
• CAS NO: 1293915-42-0
• Molecular Formula: C₃₉H₃₉ClN₈O₅
• Molecular Weight: 735.23056
• Mol File: 1293915-42-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-HexynaMide, 6-[2-[[4-aMino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyriMidin-1-yl]Methyl]-3-[(2-chlorophenyl)Methyl]-3,4-dihydro-4-oxo-5-quinazolinyl]-N,N-bis(2-Methoxyethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 5-HexynaMide, 6-[2-[[4-aMino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyriMidin-1-yl]Methyl]-3-[(2-chlorophenyl)Methyl]-3,4-dihydro-4-oxo-5-quinazolinyl]-N,N-bis(2-Methoxyethyl)-(1293915-42-0)
• EPA Substance Registry System: 5-HexynaMide, 6-[2-[[4-aMino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyriMidin-1-yl]Methyl]-3-[(2-chlorophenyl)Methyl]-3,4-dihydro-4-oxo-5-quinazolinyl]-N,N-bis(2-Methoxyethyl)-(1293915-42-0)

Safety Data

• Hazardous Substances Data: 1293915-42-0(Hazardous Substances Data)

Usage

General Description

5-HexynaMide, 6-[2-[[4-aMiNo-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyriMidin-1-yl]Methyl]-3-[(2-chlorophenyl)Methyl]-3,4-dihydro-4-oxo-5-quinazolinyl]-N,N-bis(2-Methoxyethyl)-, also known as SHR-6390, is a chemical compound with potential anticancer properties. It is a kinase inhibitor that targets multiple kinases, including VEGFR2, EGFR, and PDGFRβ, which are involved in tumor growth and angiogenesis. By inhibiting these kinases, 5-HexynaMide, 6-[2-[[4-aMiNo-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyriMidin-1-yl]Methyl]-3-[(2-chlorophenyl)Methyl]-3,4-dihydro-4-oxo-5-quinazolinyl]-N,N-bis(2-Methoxyethyl)- has the potential to suppress tumor growth and metastasis. Additionally, it has been shown to inhibit the proliferation of various cancer cell lines in preclinical studies. Further research is needed to evaluate its safety and efficacy in clinical trials for cancer treatment.

Upstream product

• 1293915-61-3 5-bromo-3-(2-chlorobenzyl)-2-(chloromethyl)quinazolin-4(3H)-one 
• 1293915-56-6 3-(3-(tert-butyldimethylsilyloxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 151266-23-8 4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidine 
• 1293915-65-7 2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-bromo-3-(2-chlorobenzyl)quinazolin-4(3H)-one 
• 1310681-87-8 N,N-bis(2-methoxyethyl)hex-5-ynamide 
• 20776-48-1 2-amino-6-chlorobenzoic acid 
• 87199-18-6 3-hydroxyphenylboronic acid 

Relevant articles and documents

NOVEL PHARMACEUTICAL FORMULATIONS

There is provided inter alia a dry powder pharmaceutical formulation for inhalation comprising: (i) 6-(2-((4-amino-3-(3-hydroxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-1-yl) methyl)-3- (2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N, N-bis(2-methoxyethyl)hex-5- ynamide or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof and solvates thereof in particulate form as active ingredient; (ii) particulate lactose as carrier; and (iii) a particulate stabilizing agent selected from metal salts of stearic acid such as magnesium stearate and metal salts of stearyl fumarate.

COMPOUNDS

The present invention relates to compounds of formula (I) and to compositions comprising the same and to the use of the compounds and their compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making said compounds.